Which orally administered antithrombotic agent is most effective for preventing venous thromboembolism after total knee arthroplasty? A propensity score-matching analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Even today, total knee arthroplasty (TKA) is associated with venous thromboembolism (VTE). The purpose of our study is to report the incidence of postoperative VTE and to compare the efficacy of commonly used orally administered antithrombotic agents. Seven hundred ad ninety-nine patients who underwent primary TKA were retrospectively reviewed. The patients were prescribed one of three antithrombotic agents: aspirin ( n = 168), rivaroxaban ( n = 117), or apixaban ( n = 514). Before surgery, patient demographics and risk factors were matched via propensity scoring. After surgery, all three groups took the agent for 7 days and underwent ultrasonography to check for VTE. The overall incidence of postoperative VTE was 15.4% (123/799). Only one patient developed symptomatic VTE. Female sex and staged bilateral TKA were risk factors for postoperative VTE. The postoperative VTE rates in the aspirin, rivaroxaban, and apixaban groups were 16.2%, 6.0%, and 17.1%, respectively, significantly lower in the rivaroxaban group ( p < 0.02). The majority of VTEs in all three groups were calf-vein thromboses. All agents showed enough efficacy as antithrombotic agents. Considering that aspirin is inexpensive, aspirin is a cost-effective option for preventing postoperative VTE.
Abstract
Even today, total knee arthroplasty (TKA) is associated with venous thromboembolism (VTE). The purpose of our study is to report the incidence of postoperative VTE and to compare the efficacy of commonly used orally administered antithrombotic agents. Seven hundred ad ninety-nine patients who underwent primary TKA were retrospectively reviewed. The patients were prescribed one of three antithrombotic agents: aspirin ( n = 168), rivaroxaban ( n = 117), or apixaban ( n = 514). Before surgery, patient demographics and risk factors were matched via propensity scoring. After surgery, all three groups took the agent for 7 days and underwent ultrasonography to check for VTE. The overall incidence of postoperative VTE was 15.4% (123/799). Only one patient developed symptomatic VTE. Female sex and staged bilateral TKA were risk factors for postoperative VTE. The postoperative VTE rates in the aspirin, rivaroxaban, and apixaban groups were 16.2%, 6.0%, and 17.1%, respectively, significantly lower in the rivaroxaban group ( p < 0.02). The majority of VTEs in all three groups were calf-vein thromboses. All agents showed enough efficacy as antithrombotic agents. Considering that aspirin is inexpensive, aspirin is a cost-effective option for preventing postoperative VTE.
참고문헌 (30)
- Rahman MM, "The relationship between osteoarthritis and cardiovascular disease in a population health survey : a cross-sectional study", BMJ Open, 3(5), pp.e002624~ (2013)
- Gadermann AM, "Comorbidity and disease burden in the National Comorbidity Survey Replication(NCS-R)", Depress Anxiety, 29(9), pp.797~806 (2012)[DOI]
- Mantilla CB, "Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty", Anesthesiology, 96(5), pp.1140~1146 (2002)[DOI]
- Kurtz S, "Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030", J Bone Joint Surg Am, 89(4), pp.780~785 (2007)[DOI]
- Prandoni P, "Long-term outcomes after deep venous thrombosis of the lower extremities", Vasc Med, 3(1), pp.57~60 (1998)[DOI]
- Klatsky AL, "Risk of pulmonary embolism and", or deep venous thrombosis in Asian-Americans, 2000, pp.85(11), 1334~1337
- Kim YH, "Incidence and natural history of deep-vein thrombosis after total knee arthroplasty. A prospective, randomised study", J Bone Joint Surg Br, 84(4), pp.566~570 (2002)[DOI]
- Bozic KJ, "Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients?", J Arthroplast, 25(7), pp.1053~1060 (2010)[DOI]
- Lassen MR, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty", N Engl J Med, 358(26), pp.2776~2786 (2008)[DOI]
- Raskob GE, "Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement : pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials", J Bone Joint Surg Br, 94(2), pp.257~264 (2012)
- Falck-Ytter Y, "Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2 Suppl), pp.e278S~e325S (2012)[DOI]
- An VV, "Aspirin as thromboprophylaxis in hip and knee arthroplasty : a systematic review and meta-analysis", J Arthroplast, 31(11), pp.2608~2616 (2016)[DOI]
- Lassen MR, "Apixaban or enoxaparin for thromboprophylaxis after knee replacement", N Engl J Med, 361(6), pp.594~604 (2009)[DOI]
- Eriksson BI, "Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty", N Engl J Med, 358(26), pp.2765~2775 (2008)[DOI]
- Anderson DR, "Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty", N Engl J Med, 378(8), pp.699~707 (2018)[DOI]
- Nieto JA, "Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty : pool-analysis of phase III randomized clinical trials", Thromb Res, 130(2), pp.183~191 (2012)[DOI]
- Alves C, "Apixaban and rivaroxaban safety after hip and knee arthroplasty : a meta-analysis", J Cardiovasc Pharmacol Ther, 17(3), pp.266~276 (2012)[DOI]
- Bala A, "Venous thromboembolism prophylaxis after TKA : aspirin, warfarin, enoxaparin, or factor Xa inhibitors?", Clin Orthop Relat Res, 475(9), pp.2205~2213 (2017)[DOI]
- Gottlieb RH, "Calf sonography for detecting deep venous thrombosis in symptomatic patients: experience and review of the literature", J Clin Ultrasound, 27(8), pp.415~420 (1999)[DOI]
- Faour M, "Low-dose aspirin is safe and effective for venous thromboembolism prophylaxis following total knee arthroplasty", J Arthroplast, 33(7s), pp.S131~S135 (2018)[DOI]
- Eriksson BI, "A once-daily, oral, direct factor Xa inhibitor, rivaroxaban(BAY 59-7939), for thromboprophylaxis after total hip replacement", Circulation, 114(22), pp.2374~2381 (2006)[DOI]
- Turpie AG, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial", Lancet, 373(9676), pp.1673~1680 (2009)[DOI]
- Moskal JT, "Intra-articular tranexamic acid in primary total knee arthroplasty : meta-analysis", J Knee Surg, 31(1), pp.56~67 (2018)[DOI]
- Arnoldussen CW, "An imaging approach to deep vein thrombosis and the lower extremity thrombosis classification", Phlebology, 27(Suppl 1), pp.143~148 (2012)[DOI]
- Fujita S, "Deep venous thrombosis after total hip or total knee arthroplasty in patients in Japan", Clin Orthop Relat Res, 375, pp.168~174 (2000)[DOI]
- Severinsen MT, "Body height and sex-related differences in incidence of venous thromboembolism : a Danish follow-up study", Eur J Intern Med, 21(4), pp.268~272 (2010)[DOI]
- Cushman M, "Hormonal factors and risk of recurrent venous thrombosis : the prevention of recurrent venous thromboembolism trial", J Thromb Haemost, 4(10), pp.2199~2203 (2006)[DOI]
- White RH, "Risk factors for venous thromboembolism after total hip and knee replacement surgery", Curr Opin Pulm Med, 8(5), pp.365~371 (2002)[DOI]
- Weill-Engerer S, "Risk factors for deep vein thrombosis in inpatients aged 65 and older : a case-control multicenter study", J Am Geriatr Soc, 52(8), pp.1299~1304 (2004)[DOI]
- White RH, "Effect of age on the incidence of venous thromboembolism after major surgery", J Thromb Haemost, 2(8), pp.1327~1333 (2004)[DOI]